MedPath

EVALUATION OF A HERBAL MASSAGE OIL IN PAIN MANAGEMENT

Not Applicable
Conditions
Health Condition 1: null- CHRONIC PAI
Registration Number
CTRI/2015/02/005559
Lead Sponsor
AYUSH ARIHANT INDUSTRIES
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
50
Inclusion Criteria

EITHER SEX AGED BETWEEN 30 TO 65 YEARS

PATIENTS WITH PRIMARY BACK, KNEE AND ANY MUSCULAR PAIN

WILLING AND ABLE TO PARTICIPATE IN THE STUDY

Exclusion Criteria

HISTORY OF ANY TRAUMA/ FRACTURED JOINT / SURGICAL/DIAGNOSTIC INTERVENTION WITH REFERENCE TO THE AFFECTED JOINT(S).

2.GROSS DISABILITY IN PERFORMING DAILY NORMAL ROUTINE I.E. BED RIDDEN PATIENTS OR CONFINED TO A WHEELCHAIR.

3.PATIENTS WITH CO MORBIDITIES SUCH AS GOUTY ARTHRITIS, RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS.

4.PATIENTS HAVING ANY DEFORMITY OF KNEE HIP OR BACK ALTERING THE GAIT AND POSTURE OF THE PATIENT.

5.PATIENTS WITH UNCONTROLLED HYPERTENSION ( >160/100 MM OF HG).

6.PATIENTS WITH UNCONTROLLED DIABETES MELLITUS{HBA1C >9%}

7.PATIENTS WITH EVIDENCE OF MALIGNANCY.

8.PATIENTS ON PROLONGED ( > 6 WEEKS) MEDICATION WITH CORTICOSTEROIDS, ANTIDEPRESSANTS, ANTICHOLINERGICS, ETC. OR ANY OTHER DRUGS THAT MAY HAVE AN INFLUENCE ON THE OUTCOME OF THE STUDY.

9.PATIENTS WHO HAVE A PAST HISTORY OF ATRIAL FIBRILLATION, ACUTE CORONARY SYNDROME, MYOCARDIAL INFARCTION, STROKE OR SEVERE ARRHYTHMIA IN THE LAST 6 MONTHS.

10.PATIENTS WITH ANY SEVERE RENAL OR HEPATIC OR ANY OTHER DISORDER WHICH MAY INTERFERE IN THE STUDY.

11.PREGNANT / LACTATING WOMAN.

12.PATIENTS WHO ARE CURRENTLY PARTICIPATING IN ANY OTHER CLINICAL TRIAL.

13.ANY OTHER CONDITION WHICH THE PRINCIPAL INVESTIGATOR THINKS MAY JEOPARDIZE THE STUDY.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
CHANGE IN PATIENTâ??S GLOBAL ASSESSMENT OF THE DISEASE ACTIVITY SCALETimepoint: AT BASELINE, 7TH DAY, 14TH DAY, 21ST DAY, 28TH DAY AND AT THE END OF FOLLOW UP AFTER 06 WEEKS
Secondary Outcome Measures
NameTimeMethod
SAFETY AND EFFICACY OF THE DRUG IN THE PATIENT WITH CHRONIC PAINTimepoint: AT BASELINE, 7TH DAY, 14TH DAY, 21ST DAY, 28TH DAY AND AT THE END OF FOLLOW UP AFTER 06 WEEKS
© Copyright 2025. All Rights Reserved by MedPath